This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, G. P. Articles by Pessina, A. C. Search for Related Content PubMed PubMed Citation Articles by Rossi, G. P. Articles by Pessina, A. C. Related Collections Related Article

The T^–786C Endothelial Nitric Oxide Synthase Genotype Predicts Cardiovascular Mortality in High-Risk Patients

Gian Paolo Rossi, MD^_*,_*, Giuseppe Maiolino, MD^_*, Mario Zanchetta, MD, Daniele Sticchi, PhD^_*, Luigi Pedon, MD, Maurizio Cesari, MD^_*, Domenico Montemurro, MD^_*, Renzo De Toni, BsD^_*, Silvia Zavattiero, PhD^_* and Achille C. Pessina, MD, PhD^_*

^_* DMCS-Internal Medicine 4
Servizio di Emodinamica and Divisione di Cardiologia Ospedale di Cittadella, University of Padua, Padua, Italy

View larger version (18K): [in a new window]   Figure 1 The histograms showed the plasma levels of nitrate/nitrite (upper panel), nitrotyrosine (middle panel), and myeloperoxidase (bottom panel) in randomly selected CC (n = 88) and TT (n = 88) patients. The panels on the left showed all of the cohort; those on the right pertain to the CC (n = 26) and TT (n = 37) patients who were not receiving nitrate for treatment of coronary artery disease (CAD).

View larger version (18K): [in a new window]   Figure 2 Results of Kaplan-Meier analysis showing cardiovascular (CV) death-free survival in the high-risk patients divided by the T–786C endothelial nitric oxide synthase (eNOS) genotype. The TT homozygous patients had a significantly lower CV death-free survival.